drugset
Drugs / Budesonide/formoterol
last change Nov 2022 re-read 9 days ago

Budesonide/formoterol

also known as Symbicort

Trials 0

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Comparator or background therapy1 trial
Phase 2/3 NCT00633919 Comparator Jul 2006 → Dec 2008 allergic disease ALK-Abelló A/S Completed No outcome recorded

Press releases naming this drug 14 releases

DateIssuerRelease
2022-11-10 Pfizer's Upjohn has merged with Mylan to form Viatris Inc. Viatris Wins Court Decision Invalidating AstraZeneca's Symbicort® Patent viatris.com ↗
2021-03-08 Pfizer's Upjohn has merged with Mylan to form Viatris Inc. Viatris Inc. and Kindeva Drug Delivery Announce FDA Tentative Approval of the First Abbreviated New Drug Application Generic Version of Symbicort® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol viatris.com ↗
2021-03-03 AstraZeneca US court decision favours Symbicort in patent litigation astrazeneca.com ↗
2021-01-26 AstraZeneca Symbicort Turbuhaler approved in China as an anti-inflammatory reliever in mild asthma astrazeneca.com ↗
2019-05-20 AstraZeneca New data show Symbicort reduces attacks in mild asthma when used as an anti-inflammatory reliever astrazeneca.com ↗
2019-05-16 AstraZeneca New data on Symbicort as a potential anti-inflammatory reliever in mild asthma to be presented at ATS 2019 astrazeneca.com ↗
2018-05-17 AstraZeneca New England Journal of Medicine publishes two trials for Symbicort as an anti-inflammatory reliever therapy ‘as needed’ in mild asthma astrazeneca.com ↗
2017-01-26 AstraZeneca Symbicort granted paediatric exclusivity in the US astrazeneca.com ↗
2016-09-06 GlaxoSmithKline GSK presents positive results from phase III FULFIL study of closed triple combination therapy FF/UMEC/VI versus Symbicort® Turbohaler® in COPD at ERS International Congress gsk.com ↗
2016-06-20 GlaxoSmithKline FULFIL study shows superiority of closed triple combination therapy FF/UMEC/VI versus Symbicort® Turbohaler® in improving lung function and health-related quality of life in COPD patients gsk.com ↗
2010-06-02 AstraZeneca FDA updates US product labels for LABA-containing medications including AstraZeneca’s SYMBICORT astrazeneca.com ↗
2010-01-12 Astellas Pharma Inc Launch of Symbicort® Turbuhaler®for the Treatment of Adult Bronchial Asthma in Japan astellas.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Budesonide/formoterol ClinicalTrials.gov intervention name — accepted as the source's own label NCT00633919 ↗
Known as Symbicort “Budesonide/formoterol inhaler (80/4.5 µg per inhalation; a combination of inhaled corticosteroids and long acting β2-agonist; Symbicort®).” NCT00633919 ↗
Route Inhaled “Budesonide/formoterol inhaler (80/4.5 µg per inhalation; a combination of inhaled corticosteroids and long acting β2-agonist; Symbicort®).” NCT00633919 ↗